The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...

CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...

Munters Group AB posted the largest decline among large stocks during the session, plunging 11.0%, followed by Camurus AB shares, which declined 9.8%. Shares of Lifco AB Series B fell 5.8%.

British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower ...